Abstract
This study uses in vitro assays and a mouse model to investigate antibacterial properties of ticagrelor to follow up findings from 2 clinical trials that showed patients taking ticagrelor for cardiovascular disease had a lower risk of infection-related death and improved lung function compared with patients treated with clopidogrel.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenosine / analogs & derivatives
-
Adenosine / pharmacology
-
Animals
-
Anti-Bacterial Agents / pharmacology*
-
Biofilms / drug effects*
-
Ciprofloxacin / pharmacology
-
Disk Diffusion Antimicrobial Tests
-
Drug Resistance, Bacterial
-
Drug Therapy, Combination
-
Enterococcus faecalis / drug effects
-
Escherichia coli / drug effects
-
Gram-Negative Bacteria / drug effects
-
Gram-Positive Bacteria / drug effects*
-
In Vitro Techniques
-
Methicillin-Resistant Staphylococcus aureus / drug effects
-
Mice
-
Mice, Inbred BALB C
-
Prosthesis-Related Infections / drug therapy
-
Pseudomonas aeruginosa / drug effects
-
Purinergic P2Y Receptor Antagonists / pharmacology*
-
Purinergic P2Y Receptor Antagonists / therapeutic use
-
Rifampin / pharmacology
-
Specific Pathogen-Free Organisms
-
Staphylococcal Infections / drug therapy
-
Staphylococcus aureus / drug effects
-
Staphylococcus epidermidis / drug effects
-
Streptococcus agalactiae / drug effects
-
Ticagrelor / pharmacology*
-
Ticagrelor / therapeutic use
-
Vancomycin / pharmacology
-
Vancomycin-Resistant Enterococci / drug effects
Substances
-
AR C124910XX
-
Anti-Bacterial Agents
-
Purinergic P2Y Receptor Antagonists
-
Ciprofloxacin
-
Vancomycin
-
Ticagrelor
-
Adenosine
-
Rifampin